Cross Country Healthcare, Inc.
NASDAQ:CCRNMedical - Care Facilities
+$0.01 today
- Market cap
- $428.06M
- Beta
- 0.45
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.13
Volume 1.78M
Average 0.64M
CCRN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cross Country Healthcare, Inc.NASDAQ: CCRN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CCRN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for CCRN, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.34M USD | -7.4% | +14.3% | 9.3% | |
| LTM Mar 2026 | $8.98M USD | -13.5% | +2.5% | 3.7% | |
| LTM Mar 2026 | $3.48M USD | +1276.3% | — | 3.2% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $0 USD | — | — | 0.0% |
AUNAAuna S.A. | LTM Mar 2026 | PEN 0 PEN | — | — | 0.0% |
| Peer median (excluding CCRN) | — | -7.4% | +8.4% | 0.0% | |
Competitors are the stored peer set for CCRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.68B | 2.8B | 2.02B | 1.34B | 1.05B |
| Cost of Revenue | 1.3B | 2.18B | 1.57B | 1.07B | 857.52M |
| Gross Profit | 375M | 624.46M | 450.41M | 274.25M | 196.78M |
| Gross Margin | 22.4% | 22.3% | 22.3% | 20.4% | 18.7% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 220.04M | 324.21M | 314.95M | 254.81M | 200.68M |
| Operating Expenses | 235.7M | 354.58M | 337.7M | 291.12M | 200.24M |
| Depreciation & Amortization | 9.45M | 12.58M | 18.35M | 17.5M | 16.79M |
| EBITDA | 154.56M | 280.06M | 129.34M | 16.77M | (64.5M) |
| EBITDA Margin | 9.2% | 10.0% | 6.4% | 1.2% | -6.1% |
| Operating Income | 139.3M | 269.88M | 112.71M | (16.87M) | (3.46M) |
| Operating Margin | 8.3% | 9.6% | 5.6% | -1.3% | -0.3% |
| Interest Income | 0 | 10K | 0 | 2.05M | 3.13M |
| Interest Expense | 6.87M | 14.39M | 8.09M | 2.19M | 2.22M |
| Other Income / Expenses | (6.1M) | (16.78M) | (9.82M) | 467K | (80.05M) |
| Income Before Tax | 133.21M | 253.1M | 102.89M | (16.4M) | (83.51M) |
| Pre-Tax Margin | 7.9% | 9.0% | 5.1% | -1.2% | -7.9% |
| Income Tax Expense | 1.21M | 67.12M | 30.26M | (1.84M) | 11.34M |
| Net Income | 132M | 185.98M | 72.63M | (14.56M) | (94.85M) |
| Net Margin | 7.9% | 6.6% | 3.6% | -1.1% | -9.0% |
| EPS (Basic) | 3.60 | 5.09 | 2.07 | (0.44) | (2.93) |
| EPS (Diluted) | 3.53 | 5.02 | 2.05 | (0.44) | (2.93) |
| Weighted Avg Shares | 36.69M | 37.01M | 35.16M | 33.38M | 32.41M |
| Weighted Avg Shares (Diluted) | 37.39M | 37.54M | 35.48M | 33.38M | 32.41M |
Cross Country Healthcare, Inc.
NASDAQ:CCRN
Intrinsic Alpha fair value
Locked
Current Price
$13.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.